Corporate Governance Basic Policy
Our mission is to contributing to all the people including patients and health professionals through our business activities. Further, we are committed to enhancing our corporate value and serving all the stakeholders through these activities. For the basis of successful implementation of these commitments, our corporate governance principles focus on the ‘compliance' and ‘transparency' by monitoring by non-executive directors and auditing by statutory auditors.
Corporate Governance Report(March 22,2024)
Corporate Governance System
External Director
(as of March 24,2024)
External Director
Stanley Lau
August 1954 (Month of birth)
Jun. 1981 | Pfizer Corp. Hong Kong |
---|---|
Apr. 1987 | Managing Director, Merck & Co. |
Oct. 1994 | General Manager, Schering Plough China Ltd. |
Oct. 1998 | Vice President, Pharmacia Searle Asia Area |
Jul. 2002 | General Manager, Baxter Healthcare International China |
Apr. 2009 | Managing Director, Haopy Pharmaceuticals Co., Ltd. |
Nov. 2010 | President, China Biologic Products, Inc. |
Mar. 2012 | COO, Eddingpharm Ltd. |
Mar. 2013 | CEO, Amsino Medical Group |
Dec. 2014 | Board Director, Solasia Pharma K.K. (present) |
Mar. 2015 | Executive Partner, BizPro International LLC (present) |
May 2015 | Senior Advisor, Wuxi SiFong Information Technology Co., Ltd (present) |
Jun. 2017 | Board Director, Xian Libang Pharmaceutical (present) |
Significant concurrent positions:
Executive Partner, BizPro International LLC
Senior Advisor, Wuxi SiFong Information Technology Co., Ltd
Board Director, Xian Libang Pharmaceutical
External Director
Norikazu Eiki
April 1948 (Month of birth)
Jun. 1973 | Matsushita Electric Works Ltd. (currently Panasonic Corporation) |
---|---|
Aug. 1979 | General Manager, Corporate Planning, Ciba-Geigy Japan Ltd. (currently Novartis Pharma K.K.) |
Jan. 1994 | General Manager, Technical Operation Division, Bayer Yakuhin Ltd. |
Mar. 1997 | Board Director, Head of Shiga Factory, Bayer Yakuhin Ltd. |
Jul. 2002 | President and CEO, Bayer Yakuhin Ltd. |
Jan. 2007 | Chairman and Representative Director, Bayer Yakuhin Ltd. |
Apr. 2010 | Chairman, Director, Bayer Yakuhin Ltd. |
May 2014 | Board Director, AnGes MG, Inc. (currently AnGes, Inc.) (present) |
Jun. 2014 | Advisor, CM Plus Corporation (present) |
Jan. 2015 | President, EIKI CONSULTING, LLC (present) |
Mar. 2015 | Board Chairman, FunPep Co., Ltd. |
Jun. 2015 | Board Director, TOWA PHARMACEUTICAL CO., LTD. (present) |
Apr. 2016 | Board Director, Solasia Pharma K.K. (present) |
Jan. 2017 | Board Director, FunPep Co., Ltd. (present) |
Jun. 2018 | Board Director, Gene Techno Science Co., Ltd. (currently Kidswell Bio Co., Ltd.present) |
Significant concurrent positions:
Board Director, AnGes, Inc.
Advisor, CM Plus Corporation
President, EIKI CONSULTING, LLC
Board Director, TOWA PHARMACEUTICAL CO., LTD.
Board Director, FunPep Co., Ltd.
Board Director, Kidswell Bio Co., Ltd.
External Director
Jiro Mizukawa
September 1952 (Month of birth)
Apr. 1976 | Marupi-Searle Co.(currently Pfizer Japan Inc.) |
---|---|
Nov. 1989 | Osaka Branch Manager and Product Manager of the Marketing Division, Searle Yakuhin K.K. (currently Pfizer Japan Inc.) |
Aug. 1992 | Deputy Head of Sales, Monsanto Japan Ltd. (currently Pfizer Japan Inc.) |
Jul. 1995 | Head of Sales of the CNS & General Care Division, Pharmacia & Upjohn Corp. (currently Pfizer Japan Inc.) |
Jul. 1999 | Head of Distribution Policy and Sales of the CNS & General Care Division, Pharmacia Corp. (currently Pfizer Inc.) |
Feb. 2003 | Head of Sales of the CNS Division, Nippon Boehringer Ingelheim Co., Ltd. |
Dec. 2003 | Corporate Officer of the Oncology and Specialty Care Division, Sanofi-Aventis K.K. (currently Sanofi K.K.) |
Nov. 2009 | Managing Director and Head of the Pharmaceuticals Division, Abbott Japan LLC (currently AbbVie GK) |
Mar. 2017 | Representative Director, LTL Pharma Co., Ltd. Significant concurrent positions: Special Advisor, LTL Pharma Co., Ltd. |
Mar. 2020 | Board Director, Solasia Pharma K.K. (present) |
External Corporate Auditor
(as of March 24,2022)
External Corporate Auditor, Full-time
Susumu Araki
August 1952 (Month of birth)
Apr. 1976 | The Tokai Bank, Ltd. (currently MUFG Bank, Ltd.) |
---|---|
June 1996 | Branch manager, Labuan Branch, The Tokai Bank, Ltd. (currently MUFG Bank, Ltd.) |
June 2001 | Branch manager, Kamata Branch, The Tokai Bank, Ltd. (currently MUFG Bank, Ltd.) |
June 2002 | General Planning Director, Financial Director, Qol Co., Ltd. |
June 2004 | Board Director, Qol Co., Ltd. |
June 2008 | Senior Executive Board Director, Qol Co., Ltd. |
Mar. 2019 | Outside Audit & Supervisory Board Member, Solasia Pharma K.K. (present) |
Significant concurrent positions:
‐
External Corporate Auditor
Yoshiyuki Yamakawa
August 1962 (Month of birth)
Apr. 1986 | Joined Nippon Life Insurance Company as Chief of the Equity Department |
---|---|
Mar. 1989 | Seconded to Nomura Securities Co., Ltd. as Chief of the IPO Department |
Sep. 1995 | Head of Corporate Planning Office, Innotech Corp. |
Sep. 2001 | Head of Corporate Planning Office, Sosei Co., Ltd. (currently Sosei Group Corp.) |
Oct. 2003 | Board Director, Executive Vice President, and CFO, Sosei Co., Ltd. |
Oct. 2004 | Representative Director, Executive Vice President, and CFO, Sosei Co., Ltd. |
Dec. 2006 | Founded Hibiki Partners Co., Ltd. Representative Director and President, Hibiki Partners Co., Ltd. (present) |
Jun. 2007 | Outside Audit & Supervisory Board Member, United Arrows Ltd. |
Jun. 2008 | Outside Board Director, Reprocell, Inc. (present) |
Mar. 2010 | Outside Board Director, D. Western Therapeutics Institute, Inc. (present) |
Mar. 2013 | Audit & Supervisory Board Member, Solasia Pharma K.K. |
Feb. 2014 | Outside Audit & Supervisory Board Member, Adventure Inc. (present) |
Mar. 2019 | Outside Audit & Supervisory Board Member, Chiome Bioscience Inc. (present) |
Mar. 2020 | Outside Audit & Supervisory Board Member, Solasia Pharma K.K. (present) |
Jun. 2020 | Outside Audit & Supervisory Board Member, TAGCyx Biotechnologies, Inc. (present) |
Significant concurrent positions:
Board Director and Chairman, Hibiki Partners Co., Ltd.
Outside Board Director, Reprocell, Inc.
Outside Board Director, D. Western Therapeutics Institute, Inc.
Outside Audit & Supervisory Board Member, Chiome Bioscience Inc.
Outside Audit & Supervisory Board Member, TAGCyx Biotechnologies, Inc.
Attended Board of Director
Nagisa Kawaida
July 1989 (Month of birth)
Dec. 2015 | Registration of Attorney (Dai-Ichi Tokyo Bar Association) |
---|---|
Jan. 2016 | Yodoyabashi & Yamagami Legal Professional Corporation |
Apr. 2021 | Partner of Yodoyabashi & Yamagami Legal Professional Corporation (Current) |
May. 2021 | Researcher of Civil Affairs Breau, Ministry of Justice (parttime) |
Jul. 2021 | Arbitrator and Compliance Committee Member of Women's Japan Basketball League (part-time)(Current) |
Significant concurrent positions:
Partner of Yodoyabashi & Yamagami Legal Professional Corporation
Arbitrator and Compliance Committee Member of Women's Japan Basketball
League
Basic Policy Regarding the Internal Control System
Basic Policy Regarding the Internal Control System
1. System for Ensuring Compliance with Laws, Regulations and the Articles of Incorporation in the Performance of Duties by Directors and Employees
- The Company is to promote the thorough understanding of the “Code of Conduct” by Directors and employees.
- The Company is to establish and maintain the internal control system to ensure the reliability of financial reporting, and conduct its assessment appropriately.
- The Company is to comprehend promptly and cope appropriately with any violation of the laws and any other material matters related to compliance in accordance with the “Rules of Whistleblowing System”.
- The Company is to take decisive actions against anti-social forces, and promote efforts for cutting off any and all relationship with anti-social forces in accordance with the “Regulations regarding Anti-Social Forces”.
- The Company is to regularly implement internal audit in accordance with the “Internal Audit Rules” and verify the above matters.
2. System for Preservation and Management of Information Relating to the Performance of the Duties by Directors
The documents and related materials concerning the Directors' performance, including the minutes of board directors meeting, shall be properly preserved and managed in accordance with the laws and the “Document Management Rules”, and made accessible to the Directors and Corporate Auditors at any time.
3. Regulations Concerning the Management of the Risk of Loss and Other Relevant Risk Management System
The Company is to take measures promptly and appropriately against the management risks affecting on the operation of the Company in accordance with the “Risk Management Rules”.
4. System for Ensuring Efficient Functioning of Directors
- The midterm-business plan shall be formulated, under which the Directors are to perform their duties, and by which the internal control are to be implemented.
- The Company is to have regular and extraordinary board director meetings as well as other meetings, using IT system, to make any decisions necessary for performing the duties in a timely manner.
5. System for Ensuring the Adequacy of Operations of the Solasia Group
(Consisting of Solasia and Its Subsidiary)
1)System for Ensuring Compliance with Laws, Regulations and the Articles of Incorporation in the Performance of Duties by Directors and Employees of the Subsidiary
- The Company is to establish the Code of Conduct of Solasia Group covering the subsidiary and promote the thorough understanding of such Code by Directors and employees of the subsidiary.
- All of the operations and activities of the subsidiary are to be subject to internal audit by the audit division.
2)System for Reporting of the Matters Relating to Business Operation Performed by Directors of the Subsidiary
- The Company is to appoint Directors and Corporate Auditors as Directors of the subsidiary and to incorporate the subsidiary's operations into the internal control system.
- The Company is to clarify for any matters that require approval from, or report to, the Company and to comply with these criteria thoroughly.
3)Regulations of the Subsidiary Concerning the Management of the Risk of Loss and Other Relevant Risk Management System
- The Company is to build the subsidiary risk management system which follows the “Risk Management Rule”.
4)System for Ensuring Efficient Functioning of Directors of the Subsidiary
- The operations of the subsidiary shall be covered by the mid-term business plan, under which the Directors of the subsidiary are to perform their duties, and by which the internal control are to be implemented.
6. Matters Regarding Employees Assisting Corporate Auditors and the Independence of Such Employees from the Directors
The Corporate Auditors may instruct the employees assisting any matters required for the audit and such assistants shall be free from the command and control of other Directors and employees.
7. System for Reporting by Directors and Employees to Corporate Auditors and Other Systems for Reporting to the Corporate Auditors
- The Company is to ensure that the Corporate Auditors attend any and all of the company meetings and obtain any information relating to the effective internal control system appropriately.
- The Directors and employees are to report their performance to the Corporate Auditors upon their request.
- The Directors and employee are to report any and all the matters that infringe of laws and regulations and could have a major impact on the finance or business of the Company, directly to the Corporate Auditors immediately after such matters recognized.
- The Company is to ensure that such Directors and employees will not be treated adversely on the ground that they have reported such matters to the Corporate Auditors.
- Upon request by the Corporate Auditors, the Company is to proceed promptly with advanced payments arising from the duties performed by them unless such payment is deemed unnecessary.
8. Other Relevant Systems for Ensuring the Proper Functioning of Audits
The Corporate Auditors are to maintain close communication and coordination with the division in charge of internal and independent auditors and the Company is to ensure that the representative director shall have meetings regularly with the Corporate Auditors to exchange opinions and information.
Basic Policy of Anti-Social Forces
Solasia Pharma K. K. has prescribed the following basic policy of anti-social forces and, through the observance of this policy by all directors and employees, will strive to ensure the appropriateness and safety of its business operations.
- We will resolutely work toward not having any relations with anti-social forces.
- We will work with specialized agencies such as police office and attorney, and handle properly in an organized way in order to prevent damages caused by anti-social forces.
- We will reject any relationship or transactions with anti-social forces.
- We will take legal actions under civil and criminal codes on the unreasonable demand from anti- social forces as necessary.
- We will not give benefits or make in secret deals with anti-social forces.